drugset
drugset / Trial / NCT06098079

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

NCT06098079 ↗

Phase 4 Active not recruiting 8600 enrolled Currax Pharmaceuticals
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).

Timeline

Start
2024-01-03
Primary completion
2029-01
Completion
2029-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupropion Small molecule 360 mg Oral
Comparator Naltrexone Small molecule 32 mg Oral

Indications

obesity disorder